Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50062 | 0.93 | ACE2 (0.39) | ACE2BLMMAPTALDH1A1CA1 | |
| SCHEMBL8813300 | 0.91 | ACE2 (0.42) | ACE2MAPK1ALDH1A1 | |
| SCHEMBL8812762 | 0.91 | ACE2 (0.42) | ACE2MAPK1ALDH1A1 | |
| SCHEMBL8811181 | 0.91 | ACE2 (0.42) | ACE2MAPK1ALDH1A1 | |
| SCHEMBL8812086 | 0.86 | BLM (0.41) | ACE2BLMMAPTPTPN1CA2 | |
| SCHEMBL8812359 | 0.86 | BLM (0.41) | ACE2BLMMAPTPTPN1CA2 | |
| SCHEMBL50856 | 0.85 | — | — | |
| SCHEMBL8814041 | 0.84 | ACE2 (0.48) | ACE2BLMMAPTPTPN1CA2 | |
| SCHEMBL8813786 | 0.84 | ACE2 (0.44) | ACE2BLMMAPTPTPN1ALDH1A1 | |
| SCHEMBL11562207 | 0.83 | MAPT (0.38) | ACE2BLMCHRNB2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372581-B1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN IND LTD (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | DAIKIN INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN INDUSTRIES, LTD. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3372581-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | Daikin Industries, Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| CN-108137498-A | Fullerene derivate and n-type semiconductor | 大金工业株式会社 | 2018-06-08 | — | — | CN | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0269963-B1 | Ferroelectric liquid crystals | HOFFMANN LA ROCHE (CH) | 1995-02-22 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0260910-B1 | 3,6-DIPHENYLPYRIDAZINES | Chisso Corporation (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5100577-A | FERROELECTRIC LIQUID CRYSTAL MIXTURES AND COMPOUNDS AS WELL AS ELECTRO-OPTICAL DEVICES EMPLOYING SAME | HOFFMAN-LA ROCHE INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-4818430-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0269963-A2 | Ferroelectric liquid crystals | F. HOFFMANN-LA ROCHE AG (CH) | 1988-06-08 | — | — | EP | disclosed |
| EP-0260910-A1 | 3,6-Diphenylpyridazines | Chisso Corporation (JP) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | SUN2, NES, L1CAM | ACE2 3629/4885BLM 2103/4885CHRNB2 87/4885 |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | SUN2, NES, L1CAM | ACE2 3629/4885BLM 2103/4885CHRNB2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.